Demonstrates adaptability of memory CD8+ T cells through γC cytokine support, indicating clinical potential.
Introduction We recently demonstrated resilience of circulating and tissue-resident memory (TRM) CD8+ T cells to loss of interleukin-7 (IL-7) signaling, revealing a compensatory relationship with its fellow common gamma chain (γC) cytokine IL-15. We found that across subsets and tissues, IL-7 and IL-15 act in concert to support memory CD8+ T cells. This confers resilience to altered availability of either cytokine, in contrast to the widely accepted model of exclusive roles for each in CD8+ T cell memory. How the broader γC cytokine family supports memory CD8+ T cells (especially TRM) in homeostasis and particularly inflammation is unclear. We hypothesize that conserved γC cytokine sensitivity confers adaptability extending beyond IL-7/15 when cytokine availability is altered. Methods We have now used cytokine therapies and infection to interrogate the broader capacity of pathogen-specific memory CD8+ T cells to adapt to cytokine availability, irrespective of homeostatic requirements. Results All γC cytokines assessed were capable of eliciting proliferation and expansion of circulating and tissue-resident memory CD8+ T cells, albeit with cytokine-, tissue-, and subset-specific nuance. This was a conserved feature of memory CD8+ T cells of different specificities and elicited by different pathogens, occurring in response to cytokines alone without cognate antigen. We observed similar behavior of bystander virus-specific memory CD8+ T cells during helminth infection. Conclusion Thus, irrespective of dependence, circulating and tissue-resident memory CD8+ T cells share cell-intrinsic sensitivity to multiple γC cytokines within tissue- and subset-specific constraints, providing additional adaptability. We propose that adaptability is a fundamental feature of CD8+ T cell memory, conferring resilience to changing tissue environments and inflammation to preserve immune memory. γC cytokine therapies are also an antigen-agnostic means to expand TRM in the laboratory and potentially the clinic. Funding Source NIAID: K22 AI177360 (NNJ), F31 AI176750 (SDO), F31 AI188630 (TAD), T32 AI007313 (KMA), K99/R00 AI139381 (HBdS), R01 AI038903 (SCJ). Damon Runyon Cancer Research Foundation DRG-2427-21 (NNJ). NCI: F30 CA250321 (KMW), K00 CA245735 (NJM), K99 CA296729 (NJM), F30 CA253992 (NVG).
No takes yet. Share an insight, caveat, or question.
Jarjour et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: